TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9610646

Group type: EXPERIMENTAL
Intervention: Transmural home care intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care programs
Number of subjects: 0
Study: 8146996

Group type: EXPERIMENTAL
Intervention: iodine brine concentrate (2 x 100 ml, daily iodine uptake approximately 9 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: isotonic NaCl
Number of subjects: 61
Study: 31615318

Group type: EXPERIMENTAL
Intervention: Antibiotics + anti-inflammatory + purified micronized flavonoid fraction (Group 2)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Purified micronized flavonoid fraction (Group 3)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Antibiotics + anti-inflammatory + alpha-blocker (Group 1)
Number of subjects: 127
Study: 29705375

Group type: EXPERIMENTAL
Intervention: Immediate invasive intervention (median time to intervention 1.4 hours)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Delayed invasive strategy (median time to intervention 61.0 hours)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Immediate invasive intervention
Number of subjects: 323

Group type: COMPARATOR
Intervention: Delayed invasive strategy
Number of subjects: 323
Study: 27846165

Group type: EXPERIMENTAL
Intervention: Lateral laparoscopic splenectomy (LLS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anterior laparoscopic splenectomy (ALS)
Number of subjects: 80
Study: 24448738

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) intervention
Number of subjects: 7166

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7166
Study: 21996130

Group type: EXPERIMENTAL
Intervention: Malleable protein matrix (MPM) from whey in low-fat yoghurt (150 g, two servings daily for 3 months)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Malleable protein matrix (MPM) from whey in low-fat yoghurt
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo yoghurt (matching control, identical in protein content 15 g/d)
Number of subjects: 197
Study: 20520295

Group type: EXPERIMENTAL
Intervention: Site-based ratings
Number of subjects: 100

Group type: COMPARATOR
Intervention: Centralized ratings
Number of subjects: 100
Study: 18535870

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study: 15838757

Group type: EXPERIMENTAL
Intervention: Athletic children (sportsmen)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Soccer players and athletes
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Judokas and wrestlers
Number of subjects: 177
Study: 12895195

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 10
Study: 10373050

Group type: EXPERIMENTAL
Intervention: C+E (5 mg . kg(‐1) caffeine + 1 mg . kg(‐1) ephedrine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Cont)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C+E
Number of subjects: 10
Study: 8714153

Group type: EXPERIMENTAL
Intervention: PPD-RT23
Number of subjects: 830

Group type: COMPARATOR
Intervention: PPD-CT68
Number of subjects: 830
Study: 2049365

Group type: EXPERIMENTAL
Intervention: AD patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 33
Study: 6407501

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (maximum 300 mg daily)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Imipramine (maximum 200 mg daily)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 151
Study: 30726897

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study: 29924912

Group type: EXPERIMENTAL
Intervention: One-way SMS
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Two-way SMS
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study: 27472747

Group type: EXPERIMENTAL
Intervention: Structured Approach Therapy (SAT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PTSD family education intervention
Number of subjects: 29
Study: 24801219

Group type: EXPERIMENTAL
Intervention: CCRC (compound Congrongyizhi Capsule) treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 41
Study: 23039709

Group type: EXPERIMENTAL
Intervention: Simplified neonatal resuscitation protocol (Helping Babies Breathe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality improvement process cycle introducing the neonatal resuscitation protocol
Number of subjects: 0
Study: 20490876

Group type: EXPERIMENTAL
Intervention: Lumbar support
Number of subjects: 0
Study: 17592393

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation exercises
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo exercises
Number of subjects: 87
Study: 15701665

Group type: EXPERIMENTAL
Intervention: Personalization
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Adaptation
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 202
Study: 11327244

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory activity monitor (Dynaport® ADL monitor)
Number of subjects: 41
Study: 9688376

Group type: EXPERIMENTAL
Intervention: 0.5% ferric hyaluronate adhesion prevention gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (Control)
Number of subjects: 0
Study: 8012141

Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% eyedrops and prednisolone 1% eyedrops
Number of subjects: 40

Group type: COMPARATOR
Intervention: indomethacin 1% eyedrops and prednisolone 1% eyedrops
Number of subjects: 40
Study: 2684659

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia without morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study: 1099895

Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 30160373

Group type: EXPERIMENTAL
Intervention: Antenatal depression screening and intervention (six-session group intervention)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Antenatal depression screening and intervention (husband participation in Session 6)
Number of subjects: 352
Study: 29091979

Group type: EXPERIMENTAL
Intervention: PlanYourLifespan.org (PYL)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 385
Study: 25827024

Group type: EXPERIMENTAL
Intervention: Radial head replacement (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Radial head repair (n = 19)
Number of subjects: 39
Study: 23688146

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for childhood anxiety
Number of subjects: 66
Study: 21855408

Group type: EXPERIMENTAL
Intervention: Evening bright light exposure (∼4000 lux) for 45 minutes daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Morning bright light exposure (∼4000 lux) for 45 minutes daily
Number of subjects: 32
Study: 19586960

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) followed by primary percutaneous coronary intervention (PCI)
Number of subjects: 1667

Group type: COMPARATOR
Intervention: Primary PCI alone
Number of subjects: 1667

Group type: EXPERIMENTAL
Intervention: TNK-pre-treated patients without reperfusion (TIMI 0-1) after PCI
Number of subjects: 1667

Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels
Number of subjects: 1667
Study: 17583796

Group type: EXPERIMENTAL
Intervention: Palaeolithic diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Consensus (Mediterranean-like) diet
Number of subjects: 29
Study: 15271117

Group type: EXPERIMENTAL
Intervention: Risk factors for symptomatic DVT identified through logistic regression analysis
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Defined score of risk factors for DVT
Number of subjects: 620
Study: 11343039

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9169338

Group type: EXPERIMENTAL
Intervention: 6% crude coal tar (CCT) ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: White petrolatum and salicylic acid
Number of subjects: 30
Study: 8228797

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 x 10(6) IU 1 h‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: tPA (100 mg 3 h‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (after 24 h on acetylsalicylic acid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20

Group type: COMPARATOR
Intervention: tPA
Number of subjects: 20
Study: 2938472

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31703672

Group type: EXPERIMENTAL
Intervention: Extemporaneous compounding practices in pharmacies
Number of subjects: 431

Group type: COMPARATOR
Intervention: Reasons for not providing extemporaneous compounding services
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Sources for compounding protocols
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Estimation of compounded medications expiration date
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Commonly compounded dosage forms
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Preparation of sterile products
Number of subjects: 431
Study: 29226630

Group type: EXPERIMENTAL
Intervention: Microneedling combined with platelet-rich plasma (PRP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Microneedling combined with trichloroacetic acid (TCA) 15% peeling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Microneedling alone (dermaroller)
Number of subjects: 24
Study: 26620191

Group type: EXPERIMENTAL
Intervention: FTO risk genotype (AA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowest fried food consumption with two copies of FTO risk variant
Number of subjects: 0

Group type: COMPARATOR
Intervention: No risk alleles with lowest fried food consumption
Number of subjects: 0
Study: 24809142

Group type: EXPERIMENTAL
Intervention: Group A (MREE <90%)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Group B (MREE 90%-110%)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Group C (MREE >110%)
Number of subjects: 158
Study: 22426910

Group type: EXPERIMENTAL
Intervention: Acaricides
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 82
Study: 19938710

Group type: EXPERIMENTAL
Intervention: Goal-oriented infusion therapy with monitoring of central hemodynamic parameters and passive leg raising test
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard infusion therapy (a combination of colloids and crystalloids (1:1) at a rate of 6‐7 ml/kg/h)
Number of subjects: 47
Study: 17466815

Group type: EXPERIMENTAL
Intervention: Multiphase Optimization Strategy (MOST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential Multiple Assignment Randomized Trial (SMART)
Number of subjects: 0
Study: 15951872

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) - autologous blood 15 mL kg(‐1) withdrawn and replaced by 6% hydroxyethylstarch (HES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (HHD) - HES administered without removal of any autologous blood
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group - no hemodilution
Number of subjects: 30
Study: 12831588

Group type: EXPERIMENTAL
Intervention: Single-dose (SD) protocol of cetrorelix (3 mg); n = 541
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD) protocol of cetrorelix (0.25 mg/day); n = 1066
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned);
Number of subjects: 1607
Study: 10382927

Group type: EXPERIMENTAL
Intervention: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 1 ml saline per nerve root sleeve (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 ml bupivacaine 0.5% combined with 40 mg methylprednisolone solution (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 40 mg methylprednisolone solution (group C)
Number of subjects: 60
Study: 8887586

Group type: EXPERIMENTAL
Intervention: Natural surfactant treatment
Number of subjects: 11
Study: 1428783

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE)
Number of subjects: 0
Study: 6321673

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy and chemotherapy (group R, 76 patients)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Preoperative chemotherapy (group C, 88 patients)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Preoperative chemotherapy (group C)
Number of subjects: 164
Study: 3948591

Group type: EXPERIMENTAL
Intervention: Developmental intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-infant intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control (preterm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control (full-term)
Number of subjects: 0
Study: 30203479

Group type: EXPERIMENTAL
Intervention: Pedometer intervention for 12 weeks
Number of subjects: 1020
Study: 27613170

Group type: EXPERIMENTAL
Intervention: Paramedic-delivered adenosine (PARA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional emergency department (ED) care
Number of subjects: 86
Study: 25747677

Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent implantation
Number of subjects: 65
Study: 23807371

Group type: COMPARATOR
Intervention: Sham with prompt laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab with prompt laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab with deferred laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone with prompt laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham with prompt laser (for eyes with PDR at baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab with prompt laser (for eyes with PDR at baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab with deferred laser (for eyes with PDR at baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone with prompt laser (for eyes with PDR at baseline)
Number of subjects: 0
Study: 21091899

Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy (CCF)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Normal colonoscopy without a cap (NCCF)
Number of subjects: 250
Study: 18201212

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.25 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.9 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16771811

Group type: EXPERIMENTAL
Intervention: TAC and BAS
Number of subjects: 72

Group type: COMPARATOR
Intervention: TAC and steroids
Number of subjects: 72
Study: 14696679

Group type: EXPERIMENTAL
Intervention: Unkei-to
Number of subjects: 0
Study: 10926623

Group type: EXPERIMENTAL
Intervention: Oral Salbutamol (12 mg/day for 3 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Gelatin placebo
Number of subjects: 8
Study: 8610732

Group type: EXPERIMENTAL
Intervention: Physician-initiated 'most important' recommendations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Physician-initiated 'major' recommendations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Patient adherence to physician-initiated 'most important' recommendations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Patient adherence to physician-initiated 'major' recommendations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Health maintenance organization (HMO) status of the patient
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Recommendation status of 'most important'
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Male patient gender
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Total number of recommendations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Total number of problems identified by CGA
Number of subjects: 139
Study: 1442343

Group type: EXPERIMENTAL
Intervention: sulglycotide
Number of subjects: 9

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 4046137

Group type: EXPERIMENTAL
Intervention: Dietetic-hygienic measures, hypolipidemic agents (mainly probucol and clofibrate), antihypertensive agents (mainly diuretics and beta-blockers)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Matched high-risk control group (n = 610)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Low-risk control group (n = 593)
Number of subjects: 612
Study: 31315668

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30010438

Group type: EXPERIMENTAL
Intervention: 1 mg morphine (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg morphine (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 60
Study: 26645190

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Prednisone plus ciclosporin
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Prednisone plus methotrexate
Number of subjects: 139
Study: 24106976

Group type: EXPERIMENTAL
Intervention: Family discord present
Number of subjects: 196
Study: 22402982

Group type: EXPERIMENTAL
Intervention: EHR tools (physician point‐of‐care alert, counseling template, order set)
Number of subjects: 30
Study: 20591813

Group type: EXPERIMENTAL
Intervention: Complete anaemia correction (haemoglobin target of 13 g/dL using darbepoetin alfa)
Number of subjects: 4038

Group type: COMPARATOR
Intervention: Placebo (with a haemoglobin rescue value of 9 g/dL)
Number of subjects: 4038
Study: 18042222

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 25
Study: 15949862

Group type: EXPERIMENTAL
Intervention: Gliclazide (GCZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide (GBC)
Number of subjects: 0
Study: 12236632

Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10069886

Group type: EXPERIMENTAL
Intervention: Professional home extermination with 2 applications of Abamectin (Avert) insecticide and directed education on cockroach allergen removal
Number of subjects: 265
Study: 7618662

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.3, 0.5, 0.7, 1.0, or 1.5 mg.kg‐1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 84
Study: 2694356

Group type: EXPERIMENTAL
Intervention: Active infrared laser therapy at 904 nm three times weekly for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naproxen sodium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dummy laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Drug treatment
Number of subjects: 30
Study: 122428

Group type: EXPERIMENTAL
Intervention: 10 μg GnRH infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 80 μg GnRH infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 800 μg GnRH infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 μg GnRH infusion in boys
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Testosterone therapy in boys
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 800 μg GnRH infusion in men
Number of subjects: 11
Study: 31060037

Group type: EXPERIMENTAL
Intervention: Water Resistance Therapy (WRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open Vocal Tract (OVT) warm-up
Number of subjects: 22
Study: 30298560

Group type: EXPERIMENTAL
Intervention: 40 mg of ketoprofen lysine salt (KLS)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 250 mg of paracetamol/acetaminophen (P)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 40 mg ketoprofen lysine salt once a day for the first 3 days of activation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151
Study: 29958003

Group type: EXPERIMENTAL
Intervention: Conjunctive partner, with competition (PWC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Conjunctive partner, no competition (PNC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Individual control (IC)
Number of subjects: 90
Study: 27358173

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg + 40 mg before PCI)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg twice before PCI)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1080
Study: 24809262

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) immediately after extubation in sequential group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation in control group
Number of subjects: 53
Study: 22210658

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg s.c. once weekly for 36-52 weeks
Number of subjects: 84
Study: 19296950

Group type: EXPERIMENTAL
Intervention: Compulsory community treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Service user perspectives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family perspectives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician perspectives
Number of subjects: 0
Study: 17609307

Group type: EXPERIMENTAL
Intervention: TPTD 20 microg/d
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: TPTD 40 microg/d
Number of subjects: 2074

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2074